Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234467 · ClinicalTrials.gov registry record · Phase 2
Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT01234467 is a Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 23 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT01234467, a Phase 2 study of Lymphoma and Diffuse Large B Cell Lymphoma, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this research study is to learn about the safety of the treatment with a combination of bendamustine and rituximab and to find out what effects, both good and bad this treatment has on DLBCL. In addition to learning about the combination of bendamustine and rituximab, the researchers are interested in learning about how this cancer treatment affects daily activities. Subjects will be asked to complete a Geriatric Assessment (GA). GAs are designed to gather information on memory, nutritional status, mental health, and level of social support. GAs are also designed to help the health care team understand how well subjects can carry out their day to day activities and to briefly describe what other medical conditions subjects may have. This assessment will help the health care team understand a subject's "functional age" (the age a subject functions at) as compared to a subject's actual age. The researchers also want to learn how chemotherapy affects the aging process in our bodies. This is done by measuring the amount of p16 in blood. Researchers want to understand if chemotherapy changes the levels of p16 in blood.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Bendamustine
Study Locations (7)
North Carolina
- Seby B. Jones Cancer Center - Boone
- University of North Carolina at Chapel Hill - Chapel Hill
- Northeast Medical Center - Concord
- Moses Cone Regional Cancer Center - Greensboro
- Leo Jenkins Cancer Center, East Carolina University Medical Center - Greenville
- Rex Healthcare - Raleigh
- Marion L. Shepard Cancer Center - Washington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234467
The ClinicalTrials.gov registry entry for NCT01234467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT01234467 reports 7 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01234467 about?
NCT01234467 is a clinical study titled "Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma". The purpose of this research study is to learn about the safety of the treatment with a combination of bendamustine and rituximab and to find out what effects, both good and bad this treatment has on DLBCL. In addition to learning about the combination of bendamustine and rituximab, the researchers ...
What is the current status of trial NCT01234467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2011-03. Estimated completion is 2016-08.
What conditions does trial NCT01234467 study?
This clinical trial studies the following conditions: Lymphoma, Diffuse Large B Cell Lymphoma, Diffuse Large Cell Lymphoma, Lymphoma, Diffuse Large-Cell.
What interventions are being tested in trial NCT01234467?
The interventions under investigation include: Rituximab (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT01234467?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01234467 being conducted?
This trial has 7 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.